Date: 2018-08-28
Type of information: Nomination
Compound: senior vice president
Company: Allogene Therapeutics (USA - CA)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On August 28, 2018, Allogene Therapeutics announced the appointment of David M. Tillett, Ph.D., as Senior Vice President, Head of Quality. In this role, Dr. Tillett will further build Allogene’s Quality system and oversee all Quality
functions. Dr. Tillett has over 25 years of experience in the production of biological drug products, with
expertise in process development, manufacturing, and quality. Dr. Tillett previously served as President of Berea Consulting, providing technical operations support to the biotechnology and pharmaceutical industry. Dr. Tillett has also served in multiple senior roles within Amgen,
including Vice President of Worldwide Quality. Prior to Amgen, he served in both manufacturing and process development roles at Synergen and was a founder and Vice-President of Sea Ag, a marine biotechnology company.
- Dr. Tillett received a B.S.Ch.E. in chemical engineering from the University of Delaware, and an M.S.Ch.E. and a Ph.D. in chemical engineering from the Georgia Institute of Technology.
Financial terms:
Latest news:
Is general: Yes
